| As of Friday's close, MDCX had 6 analyst targets pointing to a significant amount of upside potential.
In fact, with an average target of $23.50, MDCX could have over 1,000% potential upside from its closing valuation on Friday the 12th.
MarketBeat reports further that Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 1,200% from Friday's close.
Additionally, the website shares Jason McCarthy of Maxim Group has provided a $20 target suggesting 900+% potential upside from Friday's close.
Could (Nasdaq: MDCX) be undervalued from current chart levels? -----
No. 4 MDCX Potential Catalyst - Medicus Pharma Expands Global Clinical Footprint With UK Study Approval Milestone.
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
PHILADELPHIA, PA / ACCESS Newswire / November 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.
The phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in the United States can now expand into additional sites in the United Kingdom.
The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service (NHS) capacity and capability standards.
"The United Kingdom regulatory and ethical approval is another major step forward in establishing a global footprint of our novel, non-invasive treatment for BCC of the skin, which we believe represents more than $2Bn in potential market opp.," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "With clinical development programs now active across the United States, Europe, and the Middle East, we are enhancing global patient recruitment and clinical dataset which, among other things, would assist us in designing a robust pivotal program."
...
Read the full article here. -----
No. 5 MDCX Potential Catalyst - MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally.
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime
PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.
Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population.
SKINJECT™, is a novel localized immunogenic investigational precision therapy focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) of the skin.
Gorlin Syndrome is an inherited condition affecting approximately 1 in 31,000 people worldwide. Patients can develop hundreds to over one thousand basal cell carcinomas (BCCs) over their lifetime, often beginning in early childhood. The disease imposes not only a medical but also a physical, emotional and economic toll, requiring frequent scar producing surgeries, topical treatments and lifelong dermatologic care.
“Patients with Gorlin Syndrome endure a lifelong burden of recurring skin cancers that often require repeated surgeries and disfiguring treatments,” said Dr. Raza Bokhari, Executive Chairman & CEO of Medicus. “By working together with the Gorlin Syndrome Alliance, we hope to unite clinical science, regulatory leadership and advocacy to deliver hope for individuals facing lifelong burdens of Gorlin Syndrome, reinforcing our mission to deliver targeted innovation where medical need is greatest.”
...
Read the full article here. -----
(Nasdaq: MDCX) Recap - These 5 Potential Breakout Catalysts Lead The Way
No. 1 - A Low Float Could Create The Environment For Heightened Volatility.
No. 2 - Medicus Pharma Files Key Application Toward Accelerated Skin Cancer Therapy Approval.
No. 3 - An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit And More!).
No. 4 - Medicus Pharma Expands Global Clinical Footprint With UK Study Approval Milestone.
No. 5 - MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally. -----
Medicus Pharma Ltd. (Nasdaq: MDCX) has taken over controls of Monday's radar.
Updates will be following shortly. Keep your eyes peeled.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 12/14/2025 and ending on 12/15/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/mdcx-yiiay/#details | 
Tidak ada komentar:
Posting Komentar